GEMCABENE



NAME OF DRUG : GEMCABENE

ALSO KNOWN AS : GEMCABENE

LABORATORY : GEMPHIRE

STATUS AND ADVANCEMENT

Type of drug : enhance the clearance of VLDLs and may also inhibit ACC

Clinical trials advancement : Recruiting Phase 2a

Estimated time to market : 121 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON GEMCABENE

2018-02-01 : Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)

2017-12-21 : Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program

2017-01-09 : Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical StudyCompany Plans to Launch a Clinical Development Program in NAFLDNASH in 2017 based on Gemcabene’s Lipid-Lowering and Inflammation Mechanism of Action

SOME PUBLICATIONS RELATED WITH GEMCABENE

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH GEMCABENE


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE